The Middle East veterinary vaccine industry size is projected to expand at a 4% CAGR through 2033. The demand outlook for veterinary vaccines in the Middle East is US$ 627.1 million in 2023. By 2033, sales of veterinary vaccines in the Middle East are anticipated to cross a valuation of US$ 973.8 million.
| Attributes | Details |
|---|---|
| Middle East Veterinary Vaccine Industry Size in 2023 | US$ 627.1 million |
| Expected Industry Size by 2033 | US$ 973.8 million |
| Value-based CAGR from 2023 to 2033 | 4% |
Key Trends Influencing Demand through 2033
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Attributes | Details |
|---|---|
| Middle East Veterinary Vaccine Industry Size (2018) | US$ 510.8 million |
| Middle East Veterinary Vaccine Industry Size (2022) | US$ 627.1 million |
The Middle East's livestock and agriculture industries have grown significantly in recent years due to rising demand for meat, dairy, and other animal-based products. This developing industry requires the use of veterinary vaccinations to ensure the health and productivity of animals, consequently stimulating the veterinary vaccine sector's growth. Biosecurity and disease management have become critical in the livestock and agriculture industries of the Middle East. Robust procedures, including vaccination, are required to prevent disease spread within and across animal populations, fueling industry growth.
Businesses in the Middle East veterinary vaccine industry are vying to minimize the environmental effect of vaccine manufacturing and distribution as sustainability goals gain importance in the Middle East. Green practices and eco-friendly solutions are in line with the region's environmental goals. Animal disease outbreaks can have significant economic and public health consequences in the Middle East. By guaranteeing animal health through vaccination, the region mitigates these dangers while protecting the food supply and public health interests.
In the coming years, the global demand for animal-based protein is predicted to rise further as the world's population grows with rising incomes. This will increase the demand for efficient disease prevention methods such as veterinary vaccinations. Biotechnology, genetics, and immunology advancements result in the development of more accurate, efficacious, and novel veterinary vaccines. These innovations improve the industry's capacity to tackle new and emerging illnesses. Recognizing the interconnection of human, animal, and environmental health, the One Health concept is expected to foster collaboration between the veterinary and human health sectors for disease management initiatives.
Principal Consultant
| Leading Vaccine Technology in the Middle East | Attenuated Live Vaccines Technology |
|---|---|
| Total Value Share (2023) | 34.20% |
The Middle East's surging investments in biotechnology and research are boosting the domestic production of attenuated live vaccines. This coincides with the region's objective of vaccine self-sufficiency and enables customization to meet particular area disease issues. Live attenuated vaccines have proven to be useful in preventing a variety of animal illnesses. They provide a cost-effective disease management option, which is especially tempting in the Middle East's livestock and agriculture industries, where economic concerns are essential.
| Leading Animal Type in the Middle East | Livestock Animals |
|---|---|
| Total Value Share (2023) | 74.40% |
Governments around the Middle East are fiercely encouraging the expansion of the livestock sector, with many of their activities involving disease control through vaccination campaigns. The Middle East is home to a diversified animal population, which includes cattle, sheep, goats, and even camels. Each species has unique disease problems, requiring a range of vaccinations carefully tailored to each animal type's needs. Several Middle Eastern nations are making huge investments in agriculture and animal husbandry to improve food security. As the livestock industry grows, the demand for veterinary vaccinations to protect animal health and production aligns with national food security goals.
| Countries | Value-based CAGR (2023 to 2033) |
|---|---|
| KSA | 4.9% |
| UAE | 5.1% |
| Iran | 4.3% |
| Israel | 4.0% |
| Egypt | 5.3% |
Sales of veterinary vaccines in the Kingdom of Saudi Arabia (KSA) are expected to rise at a 4.9% CAGR through 2033. The Kingdom of Saudi Arabia's Vision 2030 strategic efforts focus on non-oil industries such as agriculture and healthcare. This commitment drives investments in the veterinary vaccine business, aligning with the country's economic diversification objectives. Royal support for agriculture, particularly animal husbandry, leads to greater financing and incentives for veterinary vaccine research and manufacturing. This royal encouragement has created a favorable atmosphere for the growth of the veterinary vaccine sector.
The UAE veterinary vaccines industry is projected to expand at a 5.1% CAGR through 2033. The UAE's emphasis on genetic development in livestock breeds to increase performance has increased the demand for vaccinations that protect genetically superior animals. As a result, customized vaccinations that target these breeds' specific health needs are gaining popularity. The UAE's efforts in state-of-the-art research and development, including genomics and biotechnology, have sparked the development of novel vaccinations suited to the particular animal health issues in the area. These developments are attracting both domestic and international stakeholders.
Sales of veterinary vaccines in Iran are expected to rise at a 4.3% CAGR through 2033. Iran has been subjected to international sanctions, driving self-sufficiency measures in a variety of industries, including healthcare. These self-sufficiency programs have supported the veterinary vaccine sector, leading to greater domestic manufacturing and an emphasis on innovation. The strategic location of Iran serves as a gateway for trade for Asia, Europe, and the Middle East. As trade networks increase, there is a greater demand for livestock vaccination to fulfill international animal health standards and enable commerce, hence promoting the expansion of the veterinary vaccine industry.
The demand for veterinary vaccines in Israel is likely to increase at a 4.0% CAGR through 2033. However, in light of recent geopolitical tensions between Israel and its neighboring countries, revenues of several industries are expected to be affected. Despite this, the Israeli government's significant emphasis on national security extends to biosecurity issues. The veterinary vaccine sector is vital in preserving cattle and animal populations, guaranteeing food security, and preventing bioterrorism.
The veterinary vaccine industry in Egypt is anticipated to accelerate at a 5.3% CAGR through 2033. The Egyptian government's emphasis on food security and self-sufficiency encourages investments in the livestock sector and the veterinary vaccination business. The industry is critical to ensuring the health and well-being of cattle, therefore contributing to the nation's food security goals. Egypt's participation in Pan-African agricultural projects and collaborations has resulted in a rising need for vaccinations that are compliant with regional disease control and trade standards, establishing the country as a prominent participant in African agriculture.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The Middle East veterinary vaccines industry's competitive environment is defined by a broad array of players and entities, each of which contributes to the sector's growth and development. Multinational pharmaceutical conglomerates like Zoetis, MSD Animal Health (Merck Animal Health in the United States and Canada), and Boehringer Ingelheim have a prominent presence in the region. These firms provide a wide range of vaccines, building on established brand awareness using their global reach and substantial research capabilities. Key players provide complete solutions to a wide range of animal health issues across the Middle East.
Recent Developments in the Middle East Veterinary Vaccine Industry
The Middle East veterinary vaccine market size is US$ 627.1 million in 2023.
The Middle East veterinary vaccine market is expected to rise at a 4% CAGR through 2033.
The Middle East veterinary vaccine market size will be worth US$ 973.8 million by 2033.
The demand for attenuated live vaccine technology is high in the industry.
The Middle East veterinary vaccine market size in Egypt is expected to rise at a 5.3% CAGR through 2033.
1. Executive Summary
1.1. Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Vaccine
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Vaccine, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Vaccine, 2023 to 2033
5.3.1. Attenuated Live Vaccines
5.3.2. Inactivated Vaccines
5.3.3. Toxoid Vaccines
5.3.4. DNA Vaccines
5.3.5. Recombinant Vaccines
5.3.6. Others
5.4. Y-o-Y Growth Trend Analysis By Vaccine, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Vaccine, 2023 to 2033
6. Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Animal
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Animal, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Animal, 2023 to 2033
6.3.1. Companion Animals
6.3.1.1. Canine
6.3.1.2. Avian
6.3.1.3. Feline
6.3.2. Livestock Animals
6.3.2.1. Aquatic
6.3.2.2. Bovine
6.3.2.3. Porcine
6.3.2.4. Small Ruminant
6.3.2.5. Poultry
6.3.3. Equine
6.4. Y-o-Y Growth Trend Analysis By Animal, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Animal, 2023 to 2033
7. Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Indication
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Disease Indication, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Disease Indication, 2023 to 2033
7.3.1. Foot and Mouth Disease
7.3.2. Newcastle Disease
7.3.3. PPRS
7.3.4. Canine Parvovirus
7.3.5. Brucellosis
7.3.6. Avian Influenza
7.3.7. Others
7.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Disease Indication, 2023 to 2033
8. Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By End-User, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By End-User, 2023 to 2033
8.3.1. Hospital Pharmacies
8.3.2. Veterinary Clinics
8.3.3. Private Veterinary Pharmacies
8.3.4. Others
8.4. Y-o-Y Growth Trend Analysis By End-User, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By End-User, 2023 to 2033
9. Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033
9.3.1. UAE
9.3.2. KSA
9.3.3. Turkey
9.3.4. Jordan
9.3.5. Sudan
9.3.6. Egypt
9.3.7. Rest of Middle East
9.4. Market Attractiveness Analysis By Region
10. UAE Market Analysis 2018 to 2022 and Forecast 2023 to 2033
10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.2. By Vaccine
10.2.3. By Animal
10.2.4. By Disease Indication
10.2.5. By End-User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Vaccine
10.3.3. By Animal
10.3.4. By Disease Indication
10.3.5. By End-User
10.4. Key Takeaways
11. KSA Market Analysis 2018 to 2022 and Forecast 2023 to 2033
11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.2. By Vaccine
11.2.3. By Animal
11.2.4. By Disease Indication
11.2.5. By End-User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Vaccine
11.3.3. By Animal
11.3.4. By Disease Indication
11.3.5. By End-User
11.4. Key Takeaways
12. Turkey Market Analysis 2018 to 2022 and Forecast 2023 to 2033
12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.2. By Vaccine
12.2.3. By Animal
12.2.4. By Disease Indication
12.2.5. By End-User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Vaccine
12.3.3. By Animal
12.3.4. By Disease Indication
12.3.5. By End-User
12.4. Key Takeaways
13. Jordan Market Analysis 2018 to 2022 and Forecast 2023 to 2033
13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.2. By Vaccine
13.2.3. By Animal
13.2.4. By Disease Indication
13.2.5. By End-User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Vaccine
13.3.3. By Animal
13.3.4. By Disease Indication
13.3.5. By End-User
13.4. Key Takeaways
14. Sudan Market Analysis 2018 to 2022 and Forecast 2023 to 2033
14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.2. By Vaccine
14.2.3. By Animal
14.2.4. By Disease Indication
14.2.5. By End-User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Vaccine
14.3.3. By Animal
14.3.4. By Disease Indication
14.3.5. By End-User
14.4. Key Takeaways
15. Egypt Market Analysis 2018 to 2022 and Forecast 2023 to 2033
15.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.2. By Vaccine
15.2.3. By Animal
15.2.4. By Disease Indication
15.2.5. By End-User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Vaccine
15.3.3. By Animal
15.3.4. By Disease Indication
15.3.5. By End-User
15.4. Key Takeaways
16. Rest of Market Analysis 2018 to 2022 and Forecast 2023 to 2033
16.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.2. By Vaccine
16.2.3. By Animal
16.2.4. By Disease Indication
16.2.5. By End-User
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Vaccine
16.3.3. By Animal
16.3.4. By Disease Indication
16.3.5. By End-User
16.4. Key Takeaways
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Vaccine
17.3.3. By Animal
17.3.4. By Disease Indication
17.3.5. By End-User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. JOVAC
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.1.5.2. Product Strategy
18.1.1.5.3. Channel Strategy
18.1.2. Bioveta, Inc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.2.5.2. Product Strategy
18.1.2.5.3. Channel Strategy
18.1.3. Intervac Pvt. Ltd.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.3.5.2. Product Strategy
18.1.3.5.3. Channel Strategy
18.1.4. Zoetis
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.4.5.2. Product Strategy
18.1.4.5.3. Channel Strategy
18.1.5. Elanco
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.5.5.2. Product Strategy
18.1.5.5.3. Channel Strategy
18.1.6. Merial
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.6.5.2. Product Strategy
18.1.6.5.3. Channel Strategy
18.1.7. Merck & Co. Inc.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.7.5.2. Product Strategy
18.1.7.5.3. Channel Strategy
18.1.8. Bayer Pharma AG
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.8.5.2. Product Strategy
18.1.8.5.3. Channel Strategy
18.1.9. Ceva
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.9.5.2. Product Strategy
18.1.9.5.3. Channel Strategy
18.1.10. Boehringer Ingelheim
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.10.5.2. Product Strategy
18.1.10.5.3. Channel Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Veterinary Vaccine Industry Analysis in Middle East
